These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38006433)

  • 41. Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma.
    Liu L; Zhang R; Deng J; Dai X; Zhu X; Fu Q; Zhang H; Tong Z; Zhao P; Fang W; Zheng Y; Bao X
    Cancer Immunol Immunother; 2022 Jan; 71(1):121-136. PubMed ID: 34028567
    [TBL] [Abstract][Full Text] [Related]  

  • 42. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
    Cai J; Zhou M; Xu J
    World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel application of the ferroptosis-related genes risk model associated with disulfidptosis in hepatocellular carcinoma prognosis and immune infiltration.
    Wei J; Wang J; Chen X; Zhang L; Peng M
    PeerJ; 2024; 12():e16819. PubMed ID: 38317842
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
    Wang C; Chen C; Hu W; Tao L; Chen J
    Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Deciphering the immune modulation through deep transcriptomic profiling and therapeutic implications of DNA damage repair pattern in hepatocellular carcinoma.
    Hong W; Zhang Y; Wang S; Zheng D; Hsu S; Zhou J; Fan J; Zeng Z; Wang N; Ding Z; Yu M; Gao Q; Du S
    Cancer Lett; 2024 Feb; 582():216594. PubMed ID: 38135208
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Single-Cell Sequencing Identifies the Heterogeneity of CD8+ T Cells and Novel Biomarker Genes in Hepatocellular Carcinoma.
    Wang H; Fu Y; Da BB; Xiong G
    J Healthc Eng; 2022; 2022():8256314. PubMed ID: 35449866
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A senescence-based prognostic gene signature for colorectal cancer and identification of the role of SPP1-positive macrophages in tumor senescence.
    Yu S; Chen M; Xu L; Mao E; Sun S
    Front Immunol; 2023; 14():1175490. PubMed ID: 37090726
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Deciphering the immune heterogeneity dominated by natural killer cells with prognostic and therapeutic implications in hepatocellular carcinoma.
    Guo C; Tang Y; Li Q; Yang Z; Guo Y; Chen C; Zhang Y
    Comput Biol Med; 2023 May; 158():106872. PubMed ID: 37030269
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comprehensive analysis of the potential role of necroptosis in hepatocellular carcinoma using single-cell RNA Seq and bulk RNA Seq.
    Chen J; Chen C; Tao L; Cai Y; Wang C
    J Cancer Res Clin Oncol; 2023 Nov; 149(15):13841-13853. PubMed ID: 37535163
    [TBL] [Abstract][Full Text] [Related]  

  • 50. POSTN
    Wang H; Liang Y; Liu Z; Zhang R; Chao J; Wang M; Liu M; Qiao L; Xuan Z; Zhao H; Lu L
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39067872
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic Value of Cancer-Associated Fibroblast-Related Gene Signatures in Hepatocellular Carcinoma.
    Dong W; Xie Y; Huang H
    Front Endocrinol (Lausanne); 2022; 13():884777. PubMed ID: 35733776
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Integrated analysis of single-cell and bulk RNA-sequencing reveals tumor heterogeneity and a signature based on NK cell marker genes for predicting prognosis in hepatocellular carcinoma.
    Li S; Du H; Gan D; Li X; Zao X; Ye Y
    Front Pharmacol; 2023; 14():1200114. PubMed ID: 37397471
    [No Abstract]   [Full Text] [Related]  

  • 55. Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature.
    Zhao K; Xu L; Li F; Ao J; Jiang G; Shi R; Chen F; Luo Q
    Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32789471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
    Liu Z; Zhao P
    J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Machine learning-based integration develops a neutrophil-derived signature for improving outcomes in hepatocellular carcinoma.
    Gong Q; Chen X; Liu F; Cao Y
    Front Immunol; 2023; 14():1216585. PubMed ID: 37575244
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
    Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
    Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and therapeutic response in lung squamous cell carcinoma.
    Shi X; Dong A; Jia X; Zheng G; Wang N; Wang Y; Yang C; Lu J; Yang Y
    Front Immunol; 2022; 13():992990. PubMed ID: 36311764
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.
    Zou R; Liu Y; Qiu S; Lu Y; Chen Y; Yu H; Zhu H; Zhu W; Zhu L; Feng J; Han J
    Cancer Biomark; 2023; 38(4):551-566. PubMed ID: 38007640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.